<DOC>
	<DOCNO>NCT01265680</DOCNO>
	<brief_summary>All patient operate European Hospital Heart surgery Division randomize either single dose 80.000 UI Human Recombinant Erythropoietin intravenous iron control . Primary end point amount transfuse blood . Secondary end point Hemoglobin level patient postoperative day four . Ancillary analysis regard safety 45 day cost effectiveness plan well</brief_summary>
	<brief_title>Blood Sparing Strategies : Single Shot High Dose Erythropoietin Two Days Before Heart Surgery</brief_title>
	<detailed_description>Growing evidence point blood transfusion major determinant medium long term prognosis regard heart surgery population . Moreover blood become scarce resource , thus often delay intervention due lack availability . Previous study Hospital show high dose Human Recombinant Erythropoietin ( HRE ) effectively spar transfusion even administer two day surgery . The previous protocol fragment 5 administration prove unpractical even effective . After multidisciplinal discussion nephrologists transfusionists new protocol establish : 80.000 UI single dose time arrival hospital . There exclusion criterion plan . Our primary end point amount transfuse blood . Our secondary end point Hemoglobin level patient postoperative day four . Ancillary analysis regard safety 45 day cost effectiveness plan well .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>All comer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Blood Transfusion</keyword>
	<keyword>Heart surgery</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>HRE</keyword>
</DOC>